Trxade Health Inc (NASDAQ: MEDS) Monday reported a narrower net loss for the fourth quarter of 2021 as the pharmaceutical services company's revenues
Trxade Health (MEDS) reports 20% growth in Q4 revenue; results beat estimates
Categories
Biotechnology
Catalyst Pharmaceuticals Inc. (CPRX) Q4 2021 Earnings Call Transcript
Catalyst Pharmaceuticals Inc. (NASDAQ: CPRX) Q4 2021 earnings call dated Mar. 17, 2022 Corporate Participants: Alicia Grande -- Vice President, Chief Financial Officer and
AN2 Therapeutics takes IPO route to advance pipeline. Here’s all you need to know
After starting the year on a high note, the IPO market is currently going through a slow phase mainly due to the
Bio-Path Holdings, Inc. (BPTH) Q4 2021 Earnings Call Transcript
Bio-Path Holdings, Inc. (NASDAQ: BPTH) Q4 2021 earnings call dated Mar. 11, 2022 Corporate Participants: Will O'Connor -- Investor Relations Peter Nielsen -- President, Chief Executive
Avid Bioservices, Inc. (CDMO) Q3 2022 Earnings Call Transcript
Avid Bioservices, Inc. (NASDAQ: CDMO) Q3 2022 earnings call dated Mar. 08, 2022 Corporate Participants: Tim Brons -- Investor Relations Nicholas Green -- President & Chief
Novavax, Inc. (NVAX) Q4 2021 Earnings Call Transcript
Novavax, Inc. (NASDAQ: NVAX) Q4 2021 earnings call dated Feb. 28, 2022 Corporate Participants: Silvia Taylor -- Senior Vice President of Global Corporate Affairs
FibroGen, Inc. (FGEN) Q4 2021 Earnings Call Transcript
FibroGen, Inc. (NASDAQ: FGEN) Q4 2021 earnings call dated Feb. 28, 2022 Corporate Participants: Michael Tung -- Vice President, Corporate Strategy & Investor Relations
ImmunoGen, Inc. (IMGN) FY 2021 Earnings Call Transcript
ImmunoGen, Inc. (NASDAQ: IMGN) FY 2021 earnings call dated Feb. 25, 2022 Corporate Participants: Courtney O'Konek -- Senior Director of Corporate Communications and Investor
Moderna, Inc. (MRNA) Q4 2021 Earnings Call Transcript
Moderna, Inc. (NASDAQ: MRNA) Q4 2021 earnings call dated Feb. 24, 2022 Corporate Participants: Lavina Talukdar -- Senior Vice President & Head of Investor Relations
Sage Therapeutics, Inc. (SAGE) Q4 2021 Earnings Call Transcript
Sage Therapeutics, Inc. (NASDAQ: SAGE) Q4 2021 earnings call dated Feb. 24, 2022 Corporate Participants: Helen Rubinstein -- Investor Relations Officer Barry Greene -- Chief Executive
Corcept Therapeutics Incorporated (CORT) Q4 2021 Earnings Call Transcript
Corcept Therapeutics Incorporated (NASDAQ: CORT) Q4 2021 earnings call dated Feb. 15, 2022 Corporate Participants: Atabak Mokari -- Chief Financial Officer Charles Robb -- Chief Business
Ocean Biomedical slashes IPO size. Should you invest in the stock?
The biomedical industry grew at an accelerated pace in 2021 even as healthcare systems went into overdrive amidst the COVID-induced medical emergency.
Regeneron Pharmaceuticals Inc. (REGN) Q4 2021 Earnings Call Transcript
Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) Q4 2021 earnings call dated Feb. 04, 2022 Corporate Participants: Mark Hudson -- Director, Investor Relations Leonard S. Schleifer -- Founder,
Infographic: A snapshot of Merck’s Q4 2021 earnings
Pharmaceuticals company Merck & Co., Inc. (NYSE: MRK) has reported stronger-than expected earnings and revenues for the fourth quarter. The positive outcome
BIIB Earnings: Key quarterly highlights from Biogen’s Q4 2021 financial results
Biogen Inc. (NASDAQ: BIIB) reported fourth quarter 2021 earnings results today. Total revenue decreased 4% year-over-year to $2.73 billion. GAAP net income
Arcellx readies for $140-mln IPO. Here’s all you need to know
The IPO market is recovering from the slowdown experienced towards the end of 2021, with pharma companies dominating the scene in the
Vertex Pharmaceuticals Incorporated (VRTX) Q4 2021 Earnings Call Transcript
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) Q4 2021 earnings call dated Jan. 26, 2022 Corporate Participants: Michael Partridge -- Senior Vice President of Investor Relations
INTERVIEW: Evelo’s SINTAX medicines could address a broad range of inflammatory disorders
Credit:DavidBGray on iStock Evelo Biosciences (Nasdaq:EVLO) is a clinical-stage biotechnology company that is focused on a newly uncovered area of central human
Bristol-Myers bets on product pipeline to beat patent issues. Is BMY a buy?
The pharma sector has been on a stable growth trajectory lately, and the trend gathered momentum when the pandemic-related emergency made companies
Addex Therapeutics CEO Tim Dyer: There is a $4-bil market opportunity in dyskinesia
Credit:DavidBGray on iStock Tell us a bit about your clinical programs and how they are different from the existing therapies. Addex is
Equillium CEO Bruce Steel: We are among the few evaluated in first-line GVHD treatment
Credit:DavidBGray on iStock What is Equillium all about? We started the company four years ago around our lead drug program itolizumab. My